By targeting two metabolic pathways instead of one, tirzepatide supports appetite regulation, blood sugar control and metabolic efficiency through complementary mechanisms
In the Tirzepatide versus Semaglutide cohort of 25,060 matched pairs, no statistically significant differences emerged across ocular outcomes, though Tirzepatide showed a non-significant trend (HR 0.87, 95% CI: 0.551.37, p = 0.540
This risk is particularly pronounced in individuals with a history of substance abuse
The development of IC is attributed to several principal factors, including
The National Institute on Drug Abuse is sponsoring a clinical trial this year evaluating tirzepatide, the active ingredient in Eli Lillys weight-loss drugs, as a potential treatment for cannabis use disorder